COVID-19: Time to embrace MDI+ valved-holding chambers!

J Allergy Clin Immunol. 2020 Aug;146(2):331. doi: 10.1016/j.jaci.2020.04.046. Epub 2020 May 22.

Authors

Israel Amirav¹, Michael T Newhouse²

Affiliations

¹ Pediatric Department, University of Alberta, Edmonton, Alberta, Canada. Electronic address: amirav@ualberta.ca.
² Firestone Institute for Respiratory Health, St Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada.

No abstract available

Publication types

Letter

MeSH terms

Administration, Inhalation
Albuterol / therapeutic use
Asthma / drug therapy
Betacoronavirus / pathogenicity*
Bronchodilator Agents / therapeutic use
COVID-19
Coronavirus Infections / epidemiology*
Coronavirus Infections / prevention & control*
Coronavirus Infections / transmission
Coronavirus Infections / virology
Equipment Design / instrumentation*
Humans
Metered Dose Inhalers / economics
Metered Dose Inhalers / virology*
Pandemics / prevention & control*
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / prevention & control*
Pneumonia, Viral / transmission
Pneumonia, Viral / virology
Pulmonary Disease, Chronic Obstructive / drug therapy
Risk
SARS-CoV-2

Substances

Bronchodilator Agents
Albuterol